Merck Animal Health Announces an Agreement with Cambridge Technologies to Provide Autogenous Vaccines to the U.S. Poultry Industry

Agreement brings innovative solutions to address emerging disease challenges

RAHWAY, N.J., April 1, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced it has entered into an agreement with Cambridge Technologies, an independent custom vaccine company based in Worthington, Minn., to sell and market its innovative autogenous poultry vaccines in the United States.

Cambridge Technologies uses cutting-edge molecular diagnostic and manufacturing techniques to develop custom vaccine solutions to help veterinarians and poultry producers manage emerging disease challenges. Through this agreement, Cambridge will contribute its production expertise and distribution while Merck Animal Health will provide its expansive customer reach.

“Merck Animal Health is continuously pursuing innovative ways to deliver value to our customers to improve animal health,” said Jim Tate, executive director, Integrated Livestock business in North America for Merck Animal Health. “For this agreement, we are linking together the reach of our Merck Animal Health sales and marketing teams to offer our customers the diagnostic expertise of Cambridge research scientists to provide flock-specific biologics with customized options.”

Cambridge Technologies vaccines are formulated and produced at its USDA-licensed, 37,000-square-foot manufacturing facility featuring state-of-the-art fermentation suites.

“The Cambridge team has extensive experience in diagnostics, R&D, quality control, technical support, regulatory affairs and commercial and custom vaccine production,” said Jon Mahlberg, chief operating officer for Cambridge Technologies. “Our vaccines are scientifically designed to meet the customer’s specific needs, and we are excited to combine our capabilities with those of Merck Animal Health to meet the unique needs of poultry customers.”

Production of the first vaccine batches is currently being planned. To learn more about these custom vaccine products, contact your Merck Animal Health sales or technical services representative.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

About Cambridge Technologies

Based in Worthington, MN, Cambridge Technologies brings Precision Vaccinology®, our combination of industry-leading diagnostic technology and fully customizable autogenous vaccines, to today’s innovative veterinarians and livestock producers. For more information, visit cambridgetechnologies.com and connect with us on Facebook, Instagram, LinkedIn, and X (formerly Twitter).

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

---